News source: Business Wire

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today that it has completed the divestiture of its Renal Care Business to an investment consortium led by Argos Soditic, an independent European private equity firm, and MPS Venture SGR, on behalf of the closed-end fund ‘Emilia Venture’. The new owners have purchased the entire Sorin renal care business worldwide, under the brands Bellco and Laboratoire Soludia, recognised leaders in innovative therapies for the treatment of acute and chronic dialysis patients.

The transaction completes Sorin’s program of strategic divestitures, and follows the sale of the Sorin Group endovascular business to Datascope in June, and the sale of the coronary stent business to IP Investimenti e Partecipazioni on December 1st.

"This transaction concludes our plan to restructure Sorin’s business portfolio, allowing us to better focus on our heart valves, cardiopulmonary and cardiac rhythm management businesses. We therefore look forward to accelerating innovation and growth in Sorin’s core cardiovascular franchise in 2009,” said Andre-Michel Ballester, C.E.O. of Sorin Group.

"Themanagement and employees of Sorin’s renal care business are very excited by this transaction. We believe the strategic focus brought by new ownership will enhance our ability to deliver both financial success and therapeutic benefits to our patients and customers," said Stefano Rimondi, Vice President, Renal Care Business Unit.

As a consequence of the divestiture, Sorin Group will deconsolidate retroactively as of January 1st 2008 the results of the divested business activities line by line. These results will be recognized as Earnings from discontinued operations.

The estimated impact will represent (on a full-year basis):

Revenues - € 98 million

EBIT - € 6 million

EBITDA - € 12 million

Net Debt will also be positively impacted by approximately € 10 million in 2008, as a result of the net proceeds of the disposal and debt deconsolidation, and by an additional € 38 million in 2009, as a result of the settlement of the receivables and payables associated with the Renal Care Business Unit. The net proceeds of the disposal will be used to pay down debt.

The consolidated estimated loss on disposal of assets associated with the divestiture will be approximately € 26 million, including a € 1 million restructuring charge for realignment expenses associated with the divestiture.

As a result, the Company modifies its full year 2008 guidance as follows:

Original guidance

As of January 15, 2008
Guidance as revised following

Vascular Therapy

divestiture
New Guidance following

Renal Care

divestiture
Revenues flat 1% growth 1% growth
EBIT margin >5% >6% >6%
EBITDA margin >11.5% >12% >12%
Net Debt <280 million < 277 million < 267 million

About the Sorin Group

Sorin Group (www.sorin.com) is a global company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.

With 3,500 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.

For more information, please visit: www.sorin.com or contact:
Martine Konorski

Carla Vidra

Director, Corporate Communications

Investor Relations

Sorin Group

Tel: +39 02 69969716

Tel: +33 (0)1 46 01 33 78

e-mail: carla.vidra@sorin.com

Mobile: +33 (0)6 76 12 67 73

e-mail: martine.konorski@sorin.com

About Argos Soditic

Created in 1989, Argos Soditic is an independent European private equity firm with offices in Paris, Geneva and Milan, wholly owned and operated by its partners. Argos Soditic focuses on management buy-outs and buy-ins in small and medium sized companies across Europe, but primarily in France, Italy and Switzerland. The firm has developed a unique strategy of carrying our projects that require deep involvement with the financial shareholders and managers of companies (MBO, MBI, BIMBO, spin-off, reorganization, build-up) it acquires. The group of funds managed by the firm typically takes majority stakes ranging from €5m to €50m in companies with revenues of €20m to €400m. Argos Soditic prefers to invest in companies with the capacity to become a leader in a business niche. Examples of the operations Argos Soditic has carried out include Buffet Crampon (musical instruments), Roc-Eclerc (services), Oxbow (surf wear brand), Du Pareil au Même (children’s clothing), Kermel (flame retardant chemicals), and Eau Ecarlate (stain removing brand) in France, Sparco (racing accessories) and GPP (packaging) in Italy, and Maillefer (machinery), Axyntis (specialty pharma and chemicals) and ORS (services) in Switzerland. In 2006, the firm announced the closing of a new €275m fund, Argos Soditic V, which has allowed the firm to carry out nine transactions to date: four MBOs (Driver/Sitour, GPP, FHB and Orsyp), two BIMBOs (Axyntis and Marie Laure PLV), one spin-off (Alkan) and two MBI (Chronolyss and Mertz).

For more information, please visit: www.argos-soditic.com or contact:

Mirco Dilda Partner and Francesco Pintucci, Associate: Tel: +39 0200660700

About MPS Venture SGR S.p.A

MPS Venture SGR, a company of the Montepaschi banking group, operates since 2003 in the management of closed-end investment funds for the Italian domestic territory. At present, MPS Venture, leader in Italy for the number of managed funds, manages 6 private equity funds for a total of approximately Euro 360 million.

MPS Venture SGR invests in medium size companies operating in the industrial, commercial and service industry sectors providing professional support throughout investment development projects. To date MPS Venture has made 36 investments in Italy and 16 divestments.

For more information, please visit: www.mpsventure.it or contact:

Marco Canale Tel: +39 055 2498 549, Deputy General Manager

About Medeor Associates

Medeor Associates is an advisory firm specialized in organizing M&A projects in the Healthcare field. Founding partners of Medeor Associates are Carlo Vanoli, Andrea Pavero and Maurizio Zucca.

For more information, please visit: www.medeorassociates.com

В правительстве края состоялось подписание рамочного соглашения с германской компанией «B.Braun» о строительстве в Ставрополе современного центра амбулаторного диализа.

Как рассказал заместитель министра здравоохранения CК Виктор Горбунков, это уникальный инвестиционный проект. В результате его реализации в краевом центре появится лечебное учреждение европейского уровня. Строительство полностью финансируется немецкой стороной. Оно начнется сразу после новогодних каникул и завершится через девять месяцев. Из Германии поступит и все необходимое оборудование, немецкие партнеры помогут его смонтировать и обучат наших специалистов.

В новом диализном центре смогут получать лечение одновременно 40 больных, страдающих почечной недостаточностью. Сейчас в крае потребность в диализе удовлетворяется не полностью: свыше 500 пациентов вынуждены ждать своей очереди. После ввода в эксплуатацию нового объекта ситуация изменится к лучшему.
Текст: Ольга НЕРЕТИНА

Xcorporeal, Inc объявила, что 14 декабря 2009 года она подписала соглашение о приобретении своих активов компанией Fresenius USA, Inc .......
Келли Мак Гранн, председатель и исполнительный директор компании заявил: "Мы очень рады объявить о сделке с Fresenius. Мы считаем, что Fresenius является наилучшим партнером для наших инновационных диализных технологий и эта сделка представляет собой наилучший подход к максимизации акционерной стоимости.
И с тех пор тишина....

The agreement will enable Fresenius Medical Care to initiate activities in a key Middle Eastern market. It also is aimed as a key aspect of both groups' strategy to expand their business in the region. Both entities have agreed not to disclose financial details of the transaction under discussion.

"Initiating patient care operations in the Middle East has been a defined path in our overall growth strategy, and we are convinced that the contract with SEHA is an excellent basis for the growth of Fresenius Medical Care in this region. The contract will allow our company to significantly strengthen its sales and distribution network and expand our presence in this key market," said Fresenius Medical Care's Dr. Emanuele Gatti, CEO for Europe, Latin America, the Middle East and Africa.

Saif Bader Al Qubaisi, managing director and chairman of SEHA, commented, "We are delighted to have engaged Fresenius Medical Care as our exclusive partner in the management of our renal patients. We look forward to benefiting from the knowledge and skills of the leader in this sector in building a world-class patient care organization that delivers on its promise of high-quality health care services for the people. We also look forward to pursuing other development activities in the region with our partner Fresenius Medical Care."

Dr. Ali Abdulkareem Al Obaidli, chief of clinical affairs for SEHA and a practicing renal specialist, added, "This is good news for Abu Dhabi. Bringing in the world's best providers and managers is part of our business strategy. This partnership will result in improved service levels and better outcomes for our dialysis patients."

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,599 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 202,414 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care, visit the company's website at http://www.fmc-ag.com.

About the SEHA HealthSystem and Abu Dhabi Health Services Co. PJSC (SEHA)

Abu Dhabi Health Services Co. PJSC is an independent, public joint-stock company wholly owned by the government of Abu Dhabi and created to develop the curative activities of the emirate's public health care system. The company owns and operates all the public hospitals and clinics in the emirate of Abu Dhabi which together make up the SEHA HealthSystem. Its holdings include 12 hospitals with 2,644 beds, 62 ambulatory care, family care and urgent care centers and two blood banks. SEHA is one of the largest integrated health care providers in the Middle East, employing 16,500 doctors, nurses, ancillary care and administrative personnel. SEHA means "health" in Arabic. Visit the SEHA website at http://www.seha.ae.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.